New York State Teachers Retirement System Makes New Investment in Qiagen N.V. $QGEN

New York State Teachers Retirement System acquired a new stake in shares of Qiagen N.V. (NYSE:QGEN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 9,363 shares of the company’s stock, valued at approximately $418,000.

Several other large investors have also recently made changes to their positions in the company. MAI Capital Management lifted its position in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after acquiring an additional 849 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Qiagen by 260.1% during the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after acquiring an additional 796 shares in the last quarter. Cullen Frost Bankers Inc. boosted its position in shares of Qiagen by 13,144.4% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after acquiring an additional 1,183 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after purchasing an additional 980 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Price Performance

QGEN stock opened at $55.35 on Wednesday. The stock has a market cap of $11.69 billion, a PE ratio of 28.58, a P/E/G ratio of 2.19 and a beta of 0.66. Qiagen N.V. has a 12 month low of $39.61 and a 12 month high of $57.81. The company has a 50-day moving average price of $48.39 and a 200 day moving average price of $49.41. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter last year, the firm earned $0.60 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. Equities research analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Barclays reiterated an “overweight” rating and issued a $57.89 price target (up previously from $55.79) on shares of Qiagen in a research report on Monday, December 15th. Finally, Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Two research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average price target of $52.84.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.